---
run_id: halo-evidence-vs-diagnosis-validation-v8-generic-advice-prompted-03
created: 2026-05-24
eval_type: contradiction-preservation
case_id: halo-evidence-vs-diagnosis-validation-v8
benchmark_version: halo-evidence-vs-diagnosis-validation-v8-v1
model_condition: generic_advice_prompted
run_number: 3
model_name: gemma4:31b
model_id: gemma4:31b
model_snapshot: Ollama model ID 6316f0629137
runtime: Ollama local HTTP server; version 0.24.0
provider: local
temperature: 0.7
top_p: 0.9
num_ctx: 32768
seed: 305
prompt_source: condition packet (generic_advice_prompted) - frozen added material plus frozen Advisor prompt; see run-packet.md
prompt_sha256: 5a42e17859b4a23ae36d2682474f8d0369ffc492c200375fd79a14bf3b322262
source_packet: a short generic advice-quality request, then the frozen Advisor prompt; no rubric and no sources - see run-packet.md
source_packet_sha256: 5e94f3c66f0dff57d38dd5c747b6fa04e65a3365ab875d68633add0ce68b4ce2
condition_packet_sha256: 5e94f3c66f0dff57d38dd5c747b6fa04e65a3365ab875d68633add0ce68b4ce2
output_file: model-outputs/generic_advice_prompted-03.md
judge_model_id: pending - judge receipts recorded separately under judge-packet
judge_prompt_sha256: pending - judge receipts recorded separately under judge-packet
judge_independence: pending - judge receipts recorded separately under judge-packet
raw_model_output_public_safe: true
---

# Model Output - generic_advice_prompted (run 03)

## Condition

Benchmark version `halo-evidence-vs-diagnosis-validation-v8-v1`, condition `generic_advice_prompted`, run 3 of 8. Real local-model run: `gemma4:31b` via Ollama, seed 305, on the frozen condition packet.

## Output

I recommend that you advise the CEO to choose **Option 2: The Targeted Evidence Pass.**

### Reasoning
You are currently facing a classic "false positive" in B2B SaaS: your lagging indicators (Revenue, NRR) are trending up, but your leading indicators (Front-line retention, Auditor explainability) are flashing red.

The revenue growth is an illusion created by two factors: short-term discounts and the "champion effect." When 72% of expansion is tied to discounts and usage is driven by a few "champions" rather than the people actually doing the work, you aren't seeing Product-Market Fit (PMF); you are seeing **Sales-Market Fit**. You have found a way to sell the *idea* of the product, but the users are rejecting the *utility* of the product.

Scaling now (Option 1) would be catastrophic. If you commit your annual budget to quota expansion and implementation hires for a feature with a 31% front-line retention rate, you are simply accelerating the speed at which you hit a "churn cliff." You will spend the next year hiring people to implement a tool that users abandon after seven days.

Narrowing the focus to regulated insurance (Option 3) is a tempting strategic pivot, but it is premature. You do not yet know if the "explainability" issue is a fundamental flaw in the AI logic or a simple UI/UX gap. Pivoting the entire company strategy based on a subset of trial queues—without first pausing the artificial revenue boost—is a gamble, not a strategy.

Option 2 is the only path that decouples the "hype" from the "value." By pausing discounts and instrumenting reviewer behavior, you force the product to stand on its own merits. This allows you to determine if Review Assist is a viable product or a sophisticated feature that requires a total rethink before you lock in a year of spending.

### The Tradeoffs
By choosing Option 2, you are sacrificing **momentum and narrative.**

The board is currently happy. The CEO is likely enjoying the "customer-obsessed" label. Recommending this path requires you to tell the CEO that the "upbeat story" in the board packet is misleading. You are choosing a short-term dip in sentiment and a potential slowdown in "paper" growth to avoid a long-term structural failure. You are essentially trading a comfortable present for a viable future.

### The Strongest Argument Against This Recommendation
The strongest argument against Option 2 is the **Competitive Opportunity Cost.**

In a fast-moving AI market, "pausing" to gather evidence can be fatal. If a competitor launches a similar triage tool that solves the explainability problem and scales aggressively while HelioLedger is "instrumenting behavior," you may lose the market window entirely. Sales leadership is arguing that this is a "wedge"—and in their view, a wedge is used to force a door open quickly, not to be carefully measured for fit. If the market is a "winner-take-all" land grab, the risk of being slow is higher than the risk of scaling a leaky product.

### Evidence That Would Change My Mind
I would move from Option 2 to Option 1 (Scale Broadly) if you could provide evidence that the **"Champion Usage" is actually a proxy for value.**

Currently, you see the 44% usage increase as "admins running sample queues." However, if that evidence shifted to show that these champions are using Review Assist to perform "quality audits" or "managerial oversight" that saves the *company* hundreds of hours—even if the front-line reviewers aren't using it—then the product's value proposition has shifted from a "Reviewer Tool" to a "Management Tool."

If the value is being captured at the management level (where the budget sits), the 31% front-line retention is a secondary metric. In that specific case, the "wedge" is real, the revenue is honest, and you should scale immediately.
